Vienna-based Flinn, an AI-powered software company focused on automating regulatory and quality processes in medtech, has secured $20 million in follow-on funding.
The round was led by HV Capital, with participation from US healthcare investor BHI – Bertelsmann Healthcare Investments, alongside continued backing from Cherry Ventures, Speedinvest, and SquareOne.
Responding To Growing Pressure In Healthcare Systems
The funding comes at a time when healthcare systems worldwide are facing mounting pressure from ageing populations, increasingly complex therapies, and rising administrative burdens. These factors are placing strain on public budgets and potentially limiting patient access to care.
While innovation in medical devices and pharmaceuticals continues to improve diagnostics, automation, and personalised treatments, strict regulatory and quality requirements can significantly extend development timelines and drive up costs.
Flinn aims to address this imbalance by automating regulatory workflows, data analysis, and reporting. Its AI-powered platform replaces manual, document-intensive processes with scalable systems designed to increase efficiency across global markets.
Advertisement
Automating Compliance Across The Product Lifecycle
Founded in 2022, Flinn operates with a mission to improve global health by reducing friction in regulatory and quality management. The company combines AI-driven automation with a customer-focused, experimentation-based approach to streamline compliance and accelerate product development.
Bastian Krapinger-Rüther, Co-founder and Co-CEO of Flinn, noted that regulatory and quality requirements are becoming a major cost driver throughout the medical product lifecycle. He explained that the company’s software replaces manual workflows with automated infrastructure that scales across products, markets, and regulatory frameworks.
The platform is designed to help MedTech manufacturers improve operational efficiency, shorten development timelines, and maintain compliance without compromising patient safety. By reducing administrative workloads, teams can focus more on innovation and advancing new products.
Expanding Internationally And Broadening Capabilities
With the new funding, Flinn plans to expand its platform to cover earlier development phases and commercial processes, creating an integrated compliance and quality framework that spans the full product lifecycle.
The company will also use the capital to accelerate international growth, deepening its presence across Europe and expanding into the US market.
About Flinn
Founded in 2022, Flinn develops AI-powered software that automates regulatory and quality processes for MedTech companies. Its platform enables manufacturers to launch and manage products more efficiently by replacing manual compliance workflows with scalable, automated systems, supporting innovation while maintaining high regulatory standards.
